BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Bioventus Inc.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$13.49+0.19 (+1.43%)
Close on Oct 19, 2026
- Market cap
- $955.61M
- P/E (TTM)
- 17.5
- Dividend yield
- –
Bioventus Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US Segment | $134.47M | $116.45M | $139.49M | $123.31M | $128.78M | $110.52M | $135.21M | $122.91M | $134.41M | $114.28M | $118.81M | $106.23M | 87.8% | +4.4% |
| International Segment | $18.74M | $15.64M | $18.41M | $15.34M | $18.89M | $13.36M | $18.43M | $16.06M | $16.81M | $15.18M | $16.62M | $14.57M | 12.2% | -0.8% |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $134.47M | $116.45M | $139.49M | $123.31M | $128.78M | $110.52M | $135.21M | $122.91M | $134.41M | $114.28M | $118.81M | $106.23M | 87.8% | +4.4% |
| International | $18.74M | $15.64M | $18.41M | $15.34M | $18.89M | $13.36M | $18.43M | $16.06M | $16.81M | $15.18M | $16.62M | $14.57M | 12.2% | -0.8% |
From the segment and revenue-disaggregation notes of Bioventus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.